The Hidden Costs of GLP-1 Medications in Insurance Claims

They Work. That's Not the Problem.

Let's be clear: GLP-1 drugs are the most effective pharmacological weight loss treatment we've ever seen. Semaglutide (the active ingredient in Ozempic and Wegovy) delivers around 16% body weight loss in clinical trials. Tirzepatide (Mounjaro) pushes that up to 22%.

For context, older options like orlistat (Xenical) achieved around 3 to 5%, and phentermine sat at roughly 5 to 10%, with a significant dependence risk attached.

So yes, they work. But effectiveness alone doesn't make a treatment appropriate, reasonable or necessary for a given claimant. And that distinction matters enormously in the insurance context.

The Stats That Should Concern Every Claims Team

During the webinar, IMM pharmacist Irean Baritakis walked through some reality-check numbers that every insurer should have on their radar:

• 50% of patients on a GLP-1 will experience a side effect
• 22% develop a nutritional deficiency within 6 to 12 months
• Only 20% of patients receive structured dietary education from their prescriber
• 80% of patients will not adhere to the lifestyle changes required for the treatment to be effective long-term
• Up to 40% of weight lost is muscle mass
• 99% of patients regain some level of weight after stopping treatment, some regain all if not more than baseline

That last stat is the one that should give pause. When almost every patient regains weight post-treatment, the question becomes: what was the long-term value of funding this treatment in the first place?

The Cascade Effect: One Drug, Many Liabilities

One of the critical issues we explored in the webinar is the cascade of secondary liabilities that can flow from GLP-1 use.

Take a common scenario. A claimant with a physical injury gains weight due to immobility. A GLP-1 is prescribed. They lose weight, but they also lose muscle mass and bone density because the lifestyle modifications (diet, resistance training, allied health involvement) were never implemented alongside the medication.

Then the treatment stops. The weight comes back. But now the claimant has less muscle strength and lower bone density to support that weight than they did before treatment started. The result? Increased frailty, falls risk, worsened pain, poorer cardiovascular health. A fundamentally worse position than their baseline.

If the insurer accepted liability for the weight gain and therefore the GLP-1 treatment, they may now also be liable for every condition that flows from it. Pancreatitis. Gastroparesis. Nutritional deficiencies. Osteoporosis. Surgical procedures for excess skin. Even psychological conditions triggered or worsened by the medication.

Mental Health Risks Are Real and Growing

Published research in Nature has shown that GLP-1 use can double the risk of major depression symptoms and anxiety. The FDA has recorded over 500 mental health adverse event reports related to GLP-1 drugs since 2023, including suicidal ideation.

For claimants already managing psychological injuries, or those with undiagnosed underlying conditions such as eating disorders, GLP-1 treatment can amplify existing vulnerabilities rather than resolve them.

This is especially relevant in claims where weight gain is secondary to a psychological injury involving binge eating or emotional coping behaviours. If the root psychological issues haven't been addressed, pharmacological weight loss can mask the problem while creating new ones.

The Missing Piece: An Exit Strategy

The clinical indication for GLP-1 medications is clear. They should be used as an adjunct to lifestyle changes, not as a standalone treatment. Yet what we're seeing in practice is prescribers initiating treatment without structured dietary education, without allied health involvement, and without any documented plan for discontinuation.

Drug manufacturers are actively pushing for lifelong use. Clinical trials are now extending to 104 weeks and beyond, specifically studying "maintenance" dosing. But from a pharmacist's perspective, these drugs are indicated for weight loss, not for the prevention of weight regain. Lifelong pharmacological treatment is not an appropriate strategy when the underlying lifestyle factors haven't been addressed.

For insurers, funding a GLP-1 without conditional approval criteria and a clear exit plan is effectively committing to open-ended treatment with compounding liability exposure.

What Should Insurers Be Doing?

Before approving GLP-1 funding on a claim, we strongly encourage a pharmacy review. This allows an independent clinical assessment of whether the treatment is appropriate, whether the weight is genuinely claim-related, and what the risk profile looks like for that specific claimant.

Key questions that should be answered before funding:

• Was the weight gain preexisting or claim-related?
• What was the claimant's weight at the time of injury? Is this documented?
• Is the prescribing aligned with clinical guidelines (BMI thresholds, comorbidities)?
• Are lifestyle modifications being implemented alongside pharmacological treatment?
• Is there a documented exit strategy with the prescriber?
• What are the secondary liability risks if adverse effects occur?

If the decision is to fund, a medication management service can ensure the treatment is being appropriately overseen, that exit planning is in place, and that the prescriber is engaged in a structured, time-limited approach.

What's Coming Next: Oral GLP-1s

It's worth noting that oral GLP-1 formulations are already available in the US (Rybelsus, an oral semaglutide approved for diabetes) and new oral options are in Phase 3 trials with FDA approval expected later this year. Once these reach Australia, the barrier to access drops significantly, and we expect an even greater volume of GLP-1 prescribing across claims.

Getting ahead of this now, with clear processes and clinical oversight, is the most cost-effective decision an insurer can make.

Watch the Full Webinar

For the complete discussion including detailed clinical evidence, watch the full recording:

YouTube Video Here

Get in Touch

If your team would like an education session on GLP-1 medications in claims, or any other medication-related topic, our pharmacists are available to run tailored sessions for your organisation.

Refer: Use our secure online referral form on the website

Call: Speak directly to one of our pharmacists any business day

Independent Med Management works exclusively in workers' compensation and CTP claims across Australia, partnering with all major insurers in every state and territory.